- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02369146
To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults
October 29, 2017 updated by: United BioPharma
A Phase II, Open-label, Multiple-dose Trial to Investigate the Safety and Efficacy of UB-421 Monotherapy in Substitution for Stable Antiretroviral Therapy in HIV Infected Adults
The purpose of this phase II study is to evaluate the safety, tolerability and efficacy of two multi-dose regimens of UB-421 monotherapy in replacement of HAART in HIV-1 infected adults with virological suppression.
Study Overview
Detailed Description
This is an open-label, Phase II study to evaluate the safety, tolerability and efficacy of two multi-dose regimens of UB-421 monotherapy in replacement of HAART in HIV-1 infected adults with virological suppression.
In this study, approximately 29 subjects will be enrolled to receive one of the two UB-421 regimens as the monotherapy in replacement of HARRT treatment.
Subjects assigned to Cohort 1 will receive UB-421 infusion at 10 mg/kg weekly for 8 weeks; subjects assigned to Cohort 2 will receive UB-421 infusion at 25 mg/kg bi-weekly for 16 weeks.
Study Type
Interventional
Enrollment (Actual)
29
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- HIV-1 sero-positive
- Aged 20 years or older
- Have received HAART treatment
- CD4+ T cell count ≧ 350 cells/mm3
- HIV-1 plasma RNA level remains below the limit of
- Were not breastfeeding for women
- Subjects with a negative serum pregnancy test result at screening visit for women of childbearing potential
- Subjects agree on using birth control barrier (female or male condom) during the entire study period
- Subjects sign the informed consent before undergoing any study procedures
Exclusion Criteria:
- Any active infection except for HIV, and required immediate therapy
- Any active AIDS-defining illness per Category B and Category C conditions according to the U.S. Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection
- Any documented CD4+ T cell count < 200 cells/mm3 within the past 12 weeks before screening visit
- Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history, and/or physical examination that, in the investigator's opinion, would preclude the subject from participating in this study
- Any vaccination within 8 weeks prior to the first dose of study drug
- Any immunomodulating therapy (including interferon and steroid) or systemic chemotherapy within 12 weeks prior to the first dose of study drug
- Any illicit intravenous drugs within 12 weeks prior to the first dose of study drug
- Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the subject's ability to comply with the dosing, visit schedules and protocol evaluations
- More than one change of HAART regimen because of virologic failure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cohort 1
Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
|
The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial).
Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
Other Names:
|
Experimental: cohort 2
Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly
|
The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial).
Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: 17 weeks for cohort 1, 25 weeks for cohort 2
|
17 weeks for cohort 1, 25 weeks for cohort 2
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Peak concentration of UB-421
Time Frame: 8 weeks for cohort 1, 15 weeks for cohort 2
|
8 weeks for cohort 1, 15 weeks for cohort 2
|
Trough concentration of UB-421
Time Frame: 8 weeks for cohort 1, 15 weeks for cohort 2
|
8 weeks for cohort 1, 15 weeks for cohort 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Wing Wai Wong, M.D., Taiwan, Taipei Veterans General Hospital
- Principal Investigator: Yen Hsu Chen, M.D. PhD., Kaohsiung Medical University Chung-Ho Memorial Hospital
- Principal Investigator: Hung Chin Tsai, M.D. PhD., Taiwan, Kaohsiung Veterans General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
July 1, 2016
Study Registration Dates
First Submitted
February 5, 2015
First Submitted That Met QC Criteria
February 15, 2015
First Posted (Estimate)
February 23, 2015
Study Record Updates
Last Update Posted (Actual)
October 31, 2017
Last Update Submitted That Met QC Criteria
October 29, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UBP-A202-HIV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1 Infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on UB-421
-
UBP Greater China (Shanghai) Co., LtdNot yet recruiting
-
United BioPharmaNational Taiwan University Hospital; Kaohsiung Medical University Chung-Ho... and other collaboratorsCompleted
-
UBP Greater China (Shanghai) Co., LtdNot yet recruiting
-
United BioPharmaKaohsiung Medical University Chung-Ho Memorial Hospital; Kaohsiung Veterans... and other collaboratorsCompleted
-
United BioPharmaNot yet recruiting
-
United BiomedicalTaipei Veterans General Hospital, Taiwan; Kaohsiung Veterans General Hospital. and other collaboratorsCompletedHIV-1 Infection in AdultsTaiwan
-
United BiomedicalCompletedHIV-1 Infection in Adults (Asymptomatic)Taiwan
-
National Institute of Allergy and Infectious Diseases...RecruitingMulti-Drug Resistant Hiv-1 Infection | HIV-1 InfectionUnited States
-
United BioPharmaCompleted
-
United BioPharmaNot yet recruiting